Skip to content
1 min left
0% read
Dorothyai logo

Dorothyai

Technology Company
Pittsburgh, Pennsylvania, USA
Founded 2018
2

Our search platform, Dorothy, directly compares the text of any document, such as inventions.

Share:

Our search platform, Dorothy, directly compares the text of any document, such as invention disclosures, patent claims, abstracts, product data sheets, etc., with the text of every document in the patent database. This capability will be expanded to include academic literature databases. We're developing tools that compare your text, figures, or chemical structures to figures and chemical structures associated with patent publications and academic literature.

Dorothy learns with each search and continually makes better choices, improving search accuracy and saving you time.

Frequently Asked Questions About Dorothyai

Dorothyai is a finance company. Our search platform, Dorothy, directly compares the text of any document, such as inventions.

Our search platform, Dorothy, directly compares the text of any document, such as inventions disclosures, patent claims, abstracts, product data sheets, etc., with the text of every document in the patent database, and this capability will be expanded to include academic literature databases.

We're.

Dorothyai has been operating since 2018. You can verify their legitimacy through their official website and social media presence.

Dorothyai operates in the finance sector of the cryptocurrency industry. Compare Dorothyai with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Dorothyai, research their track record (operating since 2018), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Dorothyai is based in Pittsburgh, Pennsylvania, USA, has been operating since 2018. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Dorothyai is based in Pittsburgh, Pennsylvania, USA, North America.

Dorothyai was founded in 2018. The company currently has 2 employees.

Dorothyai Details

Dorothyai Tags

More About Dorothyai

Work Model Details
Employees work from physical offices.

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m